Will AstraZeneca's COVID-19 vaccine receive FDA approval or Emergency Use Authorization (EUA) by May 1, 2021?

This is a market on whether AstraZeneca’s COVID-19 vaccine will receive regulatory approval in the USA in the form of either FDA approval OR Emergency Use Authorization, whichever comes first. This market will resolve to “Yes” if AstraZeneca’s COVID-19 vaccine receives FDA approval or EUA prior to the resolution date, May 1, 2021, 12:00 PM ET, and "No" otherwise. This market will be resolved in good faith, according to the FDA list of licensed vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), the FDA EUA list (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization), as well as any other resolution source deemed appropriate by the Markets Integrity Committee (MIC).

How trading works

Polymarket uses a central limit order book (CLOB) model — you can buy or sell shares of any outcome at the current market price, or place limit orders at your target price. All positions are settled in USDC when the market resolves.

Resolution

Markets resolve through UMA's Optimistic Oracle. After the market closes, a proposer submits a resolution, followed by a 2-hour dispute window. If no dispute is raised, the resolution is accepted. Disputed markets go to UMA token holder vote.